Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial
January 07, 2019 07:00 ET | Liquidia Technologies, Inc.
LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDANDA submission targeted for late 2019 RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2019 ...
Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
October 31, 2018 07:00 ET | Liquidia Technologies, Inc.
Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trialTwo-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019Dr. Stephen Bloch appointed as...